For research use only. Not for therapeutic Use.
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia[1].
| Catalog Number | I043171 |
| CAS Number | 921618-45-3 |
| Purity | ≥95% |
| Reference | [1]. Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15(11):2709-2721. |
